

Special Issue

Emerging Topics in *Clostridioides difficile* Infection: A One Health Problem

Message from the Guest Editor

Clostridium difficile infection (CDI) remains a substantial worldwide burden on healthcare systems, despite significant research and investment over the past four decades. We extend a warm invitation for comprehensive studies focusing on *C. difficile* isolation, characterization, and epidemiology in humans, animals, and the environment. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: AMR transmission and assessment, environmental sampling, animal transmission/infection studies, antimicrobial prescribing studies and their effect on *C. difficile* infection, transmission and carriage in humans and animals, and assessment of *C. difficile* contamination of foodstuffs. We also welcome submissions involving fundamental science laboratory studies, in vivo animal and human studies, or modeling studies. We look forward to receiving your contributions.

Guest Editor

Dr. Simon D. Baines

Department of Clinical, Pharmaceutical & Biological Science, University of Hertfordshire, Hatfield AL10 9AB, UK

Deadline for manuscript submissions

31 October 2025



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/198932

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)